7 documents

Read All
17:31 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

FDA approves AcelRx, Coherus, Pfizer Products, rebuffs Trevena's Olinvo

FDA approved products from Coherus Biosciences Inc. (NASDAQ:CHRS), AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and Pfizer Inc. (NYSE:PFE) on Nov. 2, but issued a complete response letter to an NDA from Trevena Inc. (NASDAQ:TRVN). Coherus was up...
Read More
21:15 , Nov 2, 2018 |  BC Extra  |  Company News

FDA approves AcelRx, Coherus, Pfizer products, rebuffs Trevena's Olinvo

FDA approved products from Coherus Biosciences Inc. (NASDAQ:CHRS), AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) and Pfizer Inc. (NYSE:PFE) on Friday, but issued a complete response letter to an NDA from Trevena Inc. (NASDAQ:TRVN). Coherus was up $0.70...
Read More
20:40 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

Zioxtenzo regulatory update

EMA's CHMP said Novartis withdrew its MAA for Zioxtenzo, its biosimilar of neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Pegfilgrastim is a pegylated G-CSF. Last year, FDA issued a complete response...
Read More
07:00 , Jul 18, 2016 |  BC Week In Review  |  Clinical News

CHS-1701: Phase I data

Top-line data from a single-blind, crossover, U.S. Phase I trial in 122 healthy volunteers showed that a single dose of 6 mg subcutaneous CHS-1701 met the co-primary endpoints of pharmacokinetic and pharmacodynamic bioequivalence compared to...
Read More
08:00 , Feb 8, 2016 |  BC Week In Review  |  Clinical News

CHS-1701: Phase I data

Coherus said a double-blind, U.S. Phase I trial in 303 healthy volunteers showed that 2 sequential subcutaneous doses of 6 mg CHS-1701 met the co-primary endpoints based on the development of neutralizing antibodies and the...
Read More
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

CHS-1701: Phase I data

Top-line data from a double-blind, crossover, U.S. Phase I trial in 116 healthy volunteers showed that a single subcutaneous injection of 6 mg CHS-1701 met the primary endpoint of biosimilarity to Neulasta pegfilgrastim as measured...
Read More
02:27 , Dec 18, 2014 |  BC Extra  |  Company News

FDA will review Apotex's Neulasta biosimilar

Apotex Inc. (Toronto, Ontario) said FDA accepted for filing a regulatory application for a biosimilar of pegfilgrastim . The application was submitted under the 351(k) abbreviated approval pathway under the Biosimilar Price Competition and Innovation...
Read More